基于下一代测序的高级软组织和骨肉瘤的基因组分析
Yasemin Gündoğdu1, Elif Şenocak Taşçı2, Leyla Özer3
1Department of Internal Medicine, Acıbadem MAA University, Istanbul, Türkiye.
Frontiers in oncology
|October 20, 2025
概括
下一代测序 (NGS) 在22.2%的肉瘤患者中发现了可操作的突变,使得向治疗成为可能. 这突出了NGS.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 精准医学是一门精准的医学.
背景情况:
- 软瘤,软组织 (STS) 和骨的罕见间瘤,在转移性疾病中具有有限的治疗选择和低的存活率.
- 下一代测序 (NGS) 在肉瘤管理中的临床实用性的证据仍然有限.
- 目前针对肉瘤的治疗策略往往不足,特别是在晚期.
研究的目的:
- 为了确定瘤中可向的基因组改变,以指导治疗决策.
- 探索下一代测序 (NGS) 在发现罕见癌症治疗点方面的潜力.
- 评估将基因组分析整合到肉瘤患者的临床实践中的可行性.
主要方法:
- 对81名患有STS和骨肉瘤的患者进行了回顾性多中心分析.
- 下一代测序 (NGS) 使用四种不同的套件进行,以调查突变概况.
- 分析的重点是确定可操作的突变和潜在的向疗法.
主要成果:
- 在90.1%的患者中检测到基因组改变,其中复制数放大 (26.9%) 和删除 (24.7%) 是最常见的.
- 在22.2%的患者中发现了适用于FDA批准治疗的可操作突变.
- 最常见的基因变异包括TP53 (38%),RB1 (22%) 和CDKN2A (14%). 所有患者的微观卫星稳定.
结论:
- 将NGS衍生的遗传见解集成到临床实践中,对于改善肉瘤存活率和治疗结果至关重要.
- 通过识别可向的基因组改变,NGS促进了个性化的治疗方法.
- 作为一个诊断工具,NGS被证明是有价值的,导致四名患者的重新分类,以及治疗决策.
相关概念视频
Next-generation Sequencing
The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features.
Modern Molecular Taxonomy
Advancements in molecular biology have revolutionized the identification and characterization of bacteria, with multiple methods leveraging DNA sequencing for enhanced precision. As sequencing technologies improve and costs decline, these approaches are increasingly used in clinical, environmental, and evolutionary studies.Multilocus Sequence Typing (MLST) examines several housekeeping genes, essential chromosomal genes encoding cellular functions, to distinguish strains. Approximately...


